Teacher Retirement System of Texas bought a new position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 4,866 shares of the biotechnology company’s stock, valued at approximately $286,000.
A number of other institutional investors also recently made changes to their positions in the stock. Crossmark Global Holdings Inc. raised its holdings in Enanta Pharmaceuticals by 34.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 8,300 shares of the biotechnology company’s stock worth $487,000 after purchasing an additional 2,130 shares during the period. Alps Advisors Inc. raised its holdings in Enanta Pharmaceuticals by 12.5% in the 4th quarter. Alps Advisors Inc. now owns 21,094 shares of the biotechnology company’s stock worth $1,238,000 after purchasing an additional 2,347 shares during the period. Chicago Equity Partners LLC bought a new position in Enanta Pharmaceuticals in the 4th quarter worth $733,000. Eqis Capital Management Inc. raised its holdings in Enanta Pharmaceuticals by 3.3% in the 4th quarter. Eqis Capital Management Inc. now owns 31,099 shares of the biotechnology company’s stock worth $1,825,000 after purchasing an additional 997 shares during the period. Finally, Unison Advisors LLC bought a new position in Enanta Pharmaceuticals in the 4th quarter worth $523,000. 73.25% of the stock is currently owned by institutional investors.
A number of equities analysts recently commented on the company. BidaskClub raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 14th. JPMorgan Chase & Co. lowered Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Thursday, February 8th. Royal Bank of Canada increased their price target on Enanta Pharmaceuticals to $78.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 8th. ValuEngine upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Finally, Zacks Investment Research upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $82.00 price target for the company in a research note on Monday, February 12th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Enanta Pharmaceuticals currently has an average rating of “Buy” and an average target price of $57.40.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.73. Enanta Pharmaceuticals had a return on equity of 13.33% and a net margin of 26.35%. The business had revenue of $38.11 million during the quarter, compared to analyst estimates of $27.26 million. analysts expect that Enanta Pharmaceuticals Inc will post 0.86 earnings per share for the current year.
In other news, Treasurer Paul J. Mellett sold 9,000 shares of the firm’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $86.48, for a total transaction of $778,320.00. Following the completion of the transaction, the treasurer now owns 96,458 shares in the company, valued at $8,341,687.84. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 10.56% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.